AC Immune SA ACIU

NAS: ACIU | ISIN: CH0329023102   17/05/2024
3,180 USD (-6,74%)
(-6,74%)   17/05/2024

13 mei 2024 · AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update · Persbericht

13 mei 2024 · AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease · Persbericht

14 maart 2024 · AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update · Persbericht

22 februari 2024 · AC Immune Announces Upcoming Presentations at AD/PD™ 2024 · Persbericht

22 januari 2024 · AC Immune to Regain Global Rights to Crenezumab and Semorinemab · Persbericht

3 januari 2024 · AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases · Persbericht

15 december 2023 · AC Immune Announces Pricing of Underwritten Offering of Common Shares · Persbericht

15 december 2023 · AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial · Persbericht

1 december 2023 · AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO · Persbericht

7 november 2023 · AC Immune to Present at the Jefferies 2023 London Healthcare Conference · Persbericht

3 november 2023 · AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update · Persbericht

2 november 2023 · AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023 · Persbericht

27 oktober 2023 · AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic · Persbericht

17 oktober 2023 · AC Immune Announces Upcoming Presentations at the 16th CTAD Conference · Persbericht

5 oktober 2023 · AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 · Persbericht

5 september 2023 · AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 · Persbericht

4 augustus 2023 · AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update · Persbericht

28 juli 2023 · AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023 · Persbericht

26 juli 2023 · AC Immune SA Appoints New Chief Medical Officer · Persbericht

3 juli 2023 · AC Immune Showcasing Precision Medicine Programs at AAIC 2023 · Persbericht

Mijn selecties